Sažetak
Objective: This study aimed to evaluate the therapeutic effects of glucocorticoids (GCs) combined with tacrolimus (TAC) in the treatment of Neural Epidermal Growth Factor-Like 1 (NELL1)-positive idiopathic membranous nephropathy (IMN), with a focus on clinical outcomes, nutritional status, and inflammatory response.
Methods: A total of 84 NELL1-positive IMN patients from Cangzhou Central Hospital (January 2020 – February 2024) were randomly assigned to a research group (GCs + TAC) and a control group (GCs alone). The research group received methylprednisolone (0.5g), prednisone (0.5 mg/kg), and tacrolimus (0.05 mg/kg/day), while the control group was treated with methylprednisolone and prednisone alone. Clinical parameters, including renal function, blood glucose, lipids, nutritional proteins, and cytokine levels (IL-6, IL-10, IL-2, IL-17), were measured at baseline and after six months of treatment. Nutritional status was assessed using the Nutritional Risk Screening 2002 (NRS 2002).
Results: There were no significant differences in clinical efficacy or adverse reactions between the two groups. However, the research group exhibited significant improvements in renal function, glycemic control, lipid profile, and nutritional status (P < 0.05). Furthermore, the research group showed a more favorable cytokine profile, with greater reductions in pro-inflammatory cytokines (IL-6, IL-17) and increases in anti-inflammatory cytokines (IL-10, IL-2) compared to the control group (P < 0.05). Both groups had comparable safety profiles, with no significant increase in adverse events.
Conclusion: The combination of GCs and TAC is an effective and safe therapeutic option for NELL1-positive IMN, improving clinical outcomes, maintaining nutritional stability, and modulating immune responses without increasing adverse reactions.
Ključne reči
Array
Array
Array
Array
Reference
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.